Oragenics oral care ingredient receives US patent
ProBiora3 contains three strains of beneficial oral bacteria that help in maintaining a healthy microbial balance in the mouth. Issuance of the patent enables Oragenics to immediately pursue
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).